<DOC>
	<DOCNO>NCT00000771</DOCNO>
	<brief_summary>To determine effectiveness oral paromomycin sulfate 21 day compare placebo treatment cryptosporidiosis patient HIV infection . To evaluate safety oral paromomycin two different dos . To explore whether paromomycin administer longer period provide additional benefit . In previous study , patient cryptosporidiosis demonstrate dramatic improvement paromomycin therapy .</brief_summary>
	<brief_title>A Double-Blind , Placebo-Controlled Trial Paromomycin Treatment Cryptosporidiosis Patients With Advanced HIV Disease CD4 Counts Under 150 Cells/mm3</brief_title>
	<detailed_description>In previous study , patient cryptosporidiosis demonstrate dramatic improvement paromomycin therapy . Patients randomize receive either placebo paromomycin 3 week . After initial double-blind phase , patient receive open-label paromomycin 3 week . Following 6 week therapy , patient achieve complete response receive high dose paromomycin additional 3 week , complete responder continue receive original dose additional 3 week . Complete partial responder 9 week may receive 16 additional week optional maintenance therapy dose response achieve . Treatment continue 25 week total . Patients follow week 1 , 3 , 4 , 6 , 7 , 9 , 2-4 week interval .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cryptosporidiosis</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy . Macrolides disseminate Mycobacterium avium . Atovaquone toxoplasmosis . Other antimicrobial concurrent infection . Lomotil , Imodium , deodorize opium tincture standardize regimen diarrhea . Patients must : Advanced HIV disease . Diarrhea presumptively cause Cryptosporidia . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Hypersensitivity aminoglycosides . Inability swallow capsule . Active infection due enteric pathogen . Previous diagnosis CMV MAC infection permit patient currently stabilize therapeutic regimen ( clarithromycin 500 mg bid azithromycin 600 mg daily ) . Other known cause diarrhea ( e.g. , malabsorption syndrome , gastrointestinal Kaposi 's sarcoma ) . Concurrent Medication : Excluded first 9 week study : Agents putative anticryptosporidial activity ( spiramycin , diclazuril , letrazuril , bovine colostrum ) . Octreotide acetate ( Sandostatin ) . Antidiarrheals specifically allow . Clarithromycin initiate 500 mg high azithromycin initiate 600 mg high . Prior Medication : Excluded : Paromomycin &gt; 1 g/day &gt; = 14 day prior study entry . Excluded within 14 day prior study entry : Agents putative anticryptosporidial activity ( spiramycin , diclazuril , letrazuril , bovine colostrum ) , exception macrolides permit indication . Octreotide acetate ( Sandostatin ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cryptosporidiosis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Paromomycin</keyword>
</DOC>